CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+38.34%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$2.28B
AUM Growth
+$2.28B
(+30%)
Cap. Flow
-$48.7M
Cap. Flow
% of AUM
-2.14%
Top 10 Holdings %
Top 10 Hldgs %
42%
Holding
83
New
12
Increased
7
Reduced
50
Closed
3
Top Buys
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
$153M |
| 2 |
Avidity Biosciences
RNA
|
$67.8M |
| 3 |
Arcturus Therapeutics
ARCT
|
$25.1M |
| 4 |
Pliant Therapeutics
PLRX
|
$18.8M |
| 5 |
BioNTech
BNTX
|
$11.7M |
Top Sells
Sector Composition
| 1 | Healthcare | 93.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $177M | 6.75% | 2,737,297 -319,500 | -10% | -$20.6M |
|
|
FMTX
2
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $153M | 5.82% | +3,379,373 | New | +$153M |
|
|
CCXI
3
DELISTED
ChemoCentryx, Inc.
CCXI
| $97.8M | 3.73% | 1,700,000 -325,000 | -16% | -$18.7M |
|
|
PRNB
4
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $95.1M | 3.63% | 1,590,493 -509,507 | -24% | -$30.5M |
|
5
BridgeBio Pharma
BBIO
$9.89B
| $84.5M | 3.22% | 2,590,762 -359,238 | -12% | -$11.7M |
|
6
Revolution Medicines
RVMD
$7.1B
| $82.7M | 3.16% | 2,636,661 -130,417 | -5% | -$4.09M |
|
7
Y-mAbs Therapeutics
YMAB
$388M
| $68M | 2.6% | 1,574,683 -157,517 | -9% | -$6.8M |
|
|
8
Avidity Biosciences
RNA
$5.99B
| $67.8M | 2.59% | +2,514,547 | New | +$67.8M |
|
9
Apellis Pharmaceuticals
APLS
$3.48B
| $67.5M | 2.57% | 2,066,108 -200,000 | -9% | -$6.53M |
|
|
VIE
10
DELISTED
Viela Bio, Inc. Common Stock
VIE
| $65.5M | 2.5% | 1,512,500 -250,000 | -14% | -$10.8M |
|
|
RETA
11
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $62.4M | 2.38% | 400,000 -87,206 | -18% | -$13.6M |
|
|
MYOK
12
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $58M | 2.21% | 600,000 -100,000 | -14% | -$9.66M |
|
|
XLRN
13
DELISTED
Acceleron Pharma Inc.
XLRN
| $57.2M | 2.18% | 600,000 -225,000 | -27% | -$21.4M |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $57.1M | 2.18% | 500,000 -350,000 | -41% | -$40M |
|
|
MYOV
15
DELISTED
Myovant Sciences Ltd.
MYOV
| $51.6M | 1.97% | 2,500,000 -100,000 | -4% | -$2.06M |
|
|
EIDX
16
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $50.3M | 1.92% | 1,055,302 -44,698 | -4% | -$2.13M |
|
|
BHVN
17
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $43.9M | 1.67% | 600,000 -275,551 | -31% | -$20.1M |
|
|
AGEN
18
Agenus
AGEN
$133M
| $43.2M | 1.65% | 11,000,000 -1,174,486 | -10% | -$4.62M |
|
19
Omeros
OMER
$283M
| $40.8M | 1.56% | 2,775,000 +251,300 | +10% | +$3.7M |
|
|
SRNE
20
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $40.8M | 1.56% | 6,500,000 +1,500,000 | +30% | +$9.42M |
|
21
Stoke Therapeutics
STOK
$1.08B
| $40.5M | 1.55% | 1,701,292 -8,473 | -0.5% | -$202K |
|
|
22
Arcturus Therapeutics
ARCT
$462M
| $37.4M | 1.43% | 800,000 +537,963 | +205% | +$25.1M |
|
23
Rocket Pharmaceuticals
RCKT
$354M
| $30.7M | 1.17% | 1,468,550 -100,000 | -6% | -$2.09M |
|
24
CRISPR Therapeutics
CRSP
$4.71B
| $29.4M | 1.12% | 400,000 -230,400 | -37% | -$16.9M |
|
25
Axsome Therapeutics
AXSM
$6.05B
| $28.8M | 1.1% | 350,000 -150,000 | -30% | -$12.3M |
|